SNIC
SUPR
SNIC SUPR
Mammalian cell lines for production of biologics
Dnr:

SNIC 2017/7-422

Type:

SNAC Small

Principal Investigator:

Johan Rockberg

Affiliation:

Kungliga Tekniska högskolan

Start Date:

2017-12-28

End Date:

2019-04-01

Primary Classification:

20908: Medical Biotechnology

Webpage:

Allocation

Abstract

The aim of the project is to learn what defines a good mammalian cell factory for production of protein pharmaceuticals, and by targeted genome editing improve such cell factories for use in bioreactors. Key objectives include: • Define key genomic and transcriptomic traits of six evolved versions of HEK 293 cell lines correlating with distinct bioprocess traits including change from adherent to suspension cultivation, aggregation behaviour, and growth rate • Identify key genes involved in the secretional pathway for production of human secreted proteins which express well in one of the cell lines (HEK293 or CHO) and not in the other. • Define expression profiles of cell lines with good bioprocess traits, including robustness of cells, low cell stickiness etc • Establishment of new cell lines with improved productivity and robustness for production of high quality next generation biologics • Improve drug quality of biologics by correct post translational modifications for maximal biological activity by monitoring and balancing expression of enzymes involved in folding, modification and secretion of proteins